James L Kirkland

USPTO Granted Patents = 21 (Patent Applications = 15)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 7.1

ph-index = 6

Forward Citations = 125(Granted Patents)

Company Filing History:

21 out of 1,746

Mayo Foundation for Medical Education and Research

patents

16 out of 41

Unity Biotechnology, Inc.

patents

15 out of 49

Buck Institute for Research on Aging

patents

4. 4 out of 3,688

Johns Hopkins University

patents

5. 1 out of 1

Buck Institute for Research Aging

patent

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12226416 - Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality (2025-02-18),

2. 11980616 - Treating liver disease by selectively eliminating senescent cells (2024-05-14),

3. 11925640 - Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality (2024-03-12),

4. 11517572 - Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid (2022-12-06),

5. 11351167 - Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue (2022-06-07),

6. 10517866 - Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor (2019-12-31),

7. 10478433 - Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss (2019-11-19),

8. 10478432 - Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye (2019-11-19),

9. 10413542 - Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase (2019-09-17),

10. 10328073 - Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells (2019-06-25),

11. 10328058 - Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques (2019-06-25),

12. 10258618 - Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen (2019-04-16),

13. 10251376 - Increasing healthy lifespan and delaying progression of age-related phenotypes by selectively removing senescent cells (2019-04-09),

14. 10213426 - Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population (2019-02-26),

15. 10130628 - Treatment of joint pain (2018-11-20),

Title: The Inventor James L Kirkland: Pioneering Innovations in Rochester, MN

Introduction: James L Kirkland is a distinguished inventor based in Rochester, MN, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: James L Kirkland holds several patents in the areas of medical devices, renewable energy technologies, and consumer electronics, showcasing his versatility and ingenuity.

Career Highlights: With a career spanning over two decades, James L Kirkland has established himself as a visionary inventor, with a keen eye for identifying gaps in the market and developing solutions that push the boundaries of technology.

Collaborations: Throughout his career, James L Kirkland has collaborated with leading research institutions, universities, and companies to bring his inventions to life, fostering a culture of innovation and excellence in the industry.

Conclusion: James L Kirkland's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a trailblazing inventor, shaping the future of technology and leaving a lasting impact on the world.

This text is generated by artificial intelligence and may not be accurate.